Clinical trials: Autoimmune Bullous Dermatosis
Pemphigoid, Pruritus
Pruritus and Pemphigoid in Nursing Home Patients
The primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients.
- Trial name
- SSENIOR (NCT02823067)
- Testing
- Blood sample
- Where
- Netherlands
- Volunteers
- 125 people
- Sponsor
- M.F. Jonkman
Bullous Pemphigoid
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid.
- Trial name
- ARREST-BP (NCT05061771)
- Testing
- nomacopan (rVA576)
- Where
- 12 sites in United States, Germany and 2 more
- Sponsor
- AKARI Therapeutics
Osteoporosis, Bullous Pemphigoid
Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier.
- Trial name
- DERMOS (NCT03926377)
- Testing
- bone densitometry, blood test, radiographs of the thoracic and lumbar spine
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Bullous Pemphigoid
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Bullous pemphigoid (BP) is the most common autoimmune bullous dermatosis. It mainly affects the elderly, and its cutaneous manifestations are extremely varied.
- Trial name
- NCT03636763
- Testing
- data report
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Bullous Pemphigoid, Immunotherapy
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
Immune checkpoint inhibitors (monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD- L1)) have revolutionized the treatment…
- Conditions
- Bullous Pemphigoid, Immunotherapy, Programmed Cell Death Ligand 1
- Trial name
- NCT04641884
- Testing
- Not concerned
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Nantes University Hospital
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Pemphigus, Pemphigoid
Wound Dressings for Pemphigus and Pemphigoid
The purpose of this study is to compare the efficacy of four dressings (covers) namely: gauze with petrolatum , cellulose acetate with petrolatum , pure carboxymethylcellulose with silver and nanocrystalline silver to improve the…
- Trial name
- NCT02365675
- Testing
- Cotton gauze with petrolatum, Cellulose acetate with petrolatum, Nanocrystalline silver (Acticoat)
- Where
- 2 sites in Mexico
- Volunteers
- 12 people
- Sponsor
- Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
Bullous Pemphigoid
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
This controlled multi-center randomized clinical trial, with direct individual benefit, will compare efficacy and safety of two strategies in non-localized BP care: a combined regimen using initial superpotent topical steroids…
- Trial name
- BP/MTX (NCT02313870)
- Testing
- clobetasol propionate + Methotrexate, clobetasol propionate alone
- Where
- France
- Volunteers
- 322 people
- Sponsor
- University Hospital, Montpellier
Bullous Pemphigoid, Janus Kinase Inhibitor
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering skin disease that predominantly affects the elderly population, with rare cases reported in children and adolescents.
- Conditions
- Bullous Pemphigoid, Janus Kinase Inhibitor, Corticosteroids
- Trial name
- NCT06561256
- Testing
- Janus Kinase Inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chao Ji
Pemphigus Vulgaris, Bullous Pemphigoid
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
This study assesses the disinfectant and healing promoting effect of ozonated olive oil in treatment of pemphigus vulgaris and bullous pemphigoid in comparison to conventional topical treatment with topical antibiotic.
- Trial name
- NCT05594472
- Testing
- Ozonated olive oil, Topical garamycin cream
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Pemphigoid, Bullous, Pemphigus
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other…
- Conditions
- Pemphigoid, Bullous, Pemphigus, Lupus Erythematosus, Cutaneous
- Trial name
- NCT01559155
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Bullous Pemphigoid
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease and typically affects the elderly. Clinically, BP is an intensely pruritic erythematous eruption with widespread blister formation.
- Trial name
- PB-USTE (NCT04117932)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- CHU de Reims
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Bullous Pemphigoid
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
- Trial name
- NCT00431119
- Testing
- Azathioprine or Mycophenolate mofetil
- Where
- 11 sites in Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Muenster
Bullous Pemphigoid
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development.
- Trial name
- NCT01571895
- Testing
- DF2156A
- Where
- 4 sites in Germany, Italy
- Volunteers
- 4 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pemphigus Vulgaris, Pemphigus Foliaceus
Autoimmune Blistering Diseases Study
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches.
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
- Trial name
- AIBD (NCT02753777)
- Testing
- Questionnaires
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Bullous Pemphigoid
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity…
- Trial name
- BALLAD (NCT05267600)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 129 sites in United States, Australia and 19 more
- Volunteers
- 98 people
- Sponsor
- argenx
Pemphigoid, Bullous
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
This is an open-label, pilot study evaluating the efficacy of tildrakizumab on the treatment of bullous pemphigoid (BP) in eligible patients (see detailed study protocol).
- Trial name
- NCT04465292
- Testing
- Tildrakizumab Prefilled Syringe
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Bullous Pemphigoid
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
Autoimmune bullous dermatoses include pemphigus, bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous membrane pemphigoid, lichen planus pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita and…
- Trial name
- MICROPB (NCT02874079)
- Testing
- Blood sample and cotton skin swabs
- Where
- France
- Volunteers
- 100 people
- Sponsor
- CHU de Reims
Pemphigoid
Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study.
In patients with gingival cicatricial pemphigoid (CP), clinical experience has shown that periodontal treatment is beneficial in addition to medical treatment, because the latter does not always allow optimal gingival healing.
- Trial name
- NCT04555681
- Testing
- Collection of subgingival dental plaque
- Where
- 2 sites in France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Nice